Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus tislelizumab first-line therapy for intermediate- and poor-risk advanced renal cell carcinoma
ChiCTR2300070660Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib and tislelizumab in renal cell carcinoma (RCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective remission rate. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
pazopanibtislelizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2300070660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070660.